TY - JOUR T1 - Efficacy of tofacitinib in synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: a pilot study with clinical and MRI evaluation JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 1255 LP - 1257 DO - 10.1136/annrheumdis-2020-217250 VL - 79 IS - 9 AU - Yueting Li AU - Jianwei Huo AU - Yihan Cao AU - Meiyan Yu AU - Yanan Zhang AU - Zhaohui Li AU - Chen Li AU - Wen Zhang Y1 - 2020/09/01 UR - http://ard.bmj.com/content/79/9/1255.abstract N2 - Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a chronic inflammatory disease that severely affects patients’ quality of life. Therapies including tumour necrosis factor inhibitors (TNFi) and bisphosphonates (BPs) yield variable efficacy.1 Tofacitinib, a Janus kinase inhibitor, may suppress osteoclast-mediated joint damage by inhibiting the RANKL pathway.2 A previous study proved the safety and efficacy of tofacitinib in psoriatic arthritis resistant to TNFi over 3 months.3 Additionally, we reported a case where tofacitinib in combination with methotrexate and Tripterygium wilfordii Hook was effective in SAPHO syndrome.4 To further explore tofacitinib efficacy in SAPHO syndrome, we retrospectively reviewed the medical records of patients enrolled from January 2019 to December 2019 in our dynamic cohort of SAPHO syndrome.5 Patients were included if they: (1) received tofacitinib without concomitant TNFi, BPs, or other disease-modifying antirheumatic drugs and (2) had complete clinical data and MRI of SAPHO-related lesions with pain before (within 1 week) and during tofacitinib treatment. The pain visual analogue scale (VAS) score and … ER -